nizatidine

Summary

Summary: A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers.

Top Publications

  1. El Yazbi F, Gazy A, Mahgoub H, el Sayed M, Youssef R. Spectrophotometric and titrimetric determination of nizatidine in capsules. J Pharm Biomed Anal. 2003;31:1027-34 pubmed
    Four simple and accurate methods are described for the determination of nizatidine (NIZ) in pharmaceutical preparations...
  2. Hassan E, Belal F. Kinetic spectrophotometric determination of nizatidine and ranitidine in pharmaceutical preparations. J Pharm Biomed Anal. 2002;27:31-8 pubmed
    A new simple and sensitive kinetic spectrophotometric method is described for analysis of nizatidine (I) and ranitidine (II)...
  3. Kovacs T, Wilcox C, DeVault K, Miska D, Bochenek W. Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: a randomized, active-controlled, double-blind study. Aliment Pharmacol Ther. 2002;16:2043-52 pubmed
    ..To compare the efficacy and safety of pantoprazole vs. nizatidine for the treatment of symptomatic gastro-oesophageal reflux disease and endoscopically documented erosive ..
  4. Dahan A, Sabit H, Amidon G. The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport. AAPS J. 2009;11:205-13 pubmed publisher
    ..cell efflux transport processes that are involved in the intestinal transport of the H(2) receptor antagonist nizatidine. The intestinal epithelial efflux transport mechanisms of nizatidine were investigated and characterized across ..
  5. Assunção S, Ruschel S, Rosa L, Campos J, Alves M, Bracco O, et al. Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine. Rev Bras Psiquiatr. 2006;28:270-6 pubmed
    Weight gain is associated with treatment with many psychotropic agents. Nizatidine, H2 receptor antagonist, has been proposed to have weight-reducing effects...
  6. Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain. Hum Psychopharmacol. 2003;18:457-61 pubmed
    It has been reported that nizatidine may reduce the weight gain in schizophrenic patients receiving olanzapine treatment. Previous studies have demonstrated a relation between olanzapine-induced weight gain and serum leptin levels...
  7. Pare P, Armstrong D, Pericak D, Pyzyk M. Pantoprazole rapidly improves health-related quality of life in patients with heartburn: a prospective, randomized, double blind comparative study with nizatidine. J Clin Gastroenterol. 2003;37:132-8 pubmed
    ..To evaluate changes in HRQoL during treatment with pantoprazole or nizatidine in patients with GERD. This was a prospective, randomized, double blind Canadian multicenter study...
  8. Cavazzoni P, Tanaka Y, Roychowdhury S, Breier A, Allison D. Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol. 2003;13:81-5 pubmed
    Weight gain is associated with treatment with olanzapine and other psychotropic agents. Nizatidine, a histamine H-2 receptor antagonist, has been proposed to have weight-reducing effects...
  9. Adachi K, Ono M, Kawamura A, Yuki M, Fujishiro H, Kinoshita Y. Nizatidine and cisapride enhance salivary secretion in humans. Aliment Pharmacol Ther. 2002;16:297-301 pubmed
    ..Both nizatidine and cisapride have been reported to increase acetylcholine concentrations in the cholinergic system...

More Information

Publications80

  1. Carlson M, Tschanz J, Norton M, Welsh Bohmer K, Martin B, Breitner J. H2 histamine receptor blockade in the treatment of Alzheimer disease: a randomized, double-blind, placebo-controlled trial of nizatidine. Alzheimer Dis Assoc Disord. 2002;16:24-30 pubmed
    To evaluate the efficacy of nizatidine, a histamine H2-blocking drug, in delaying the progression of cognitive impairment in older adults with Alzheimer disease (AD). A one-year, randomized, double-blind, placebo-controlled trial...
  2. Hamamoto N, Hashimoto T, Adachi K, Hirakawa K, Ishihara S, Inoue H, et al. Comparative study of nizatidine and famotidine for maintenance therapy of erosive esophagitis. J Gastroenterol Hepatol. 2005;20:281-6 pubmed
    ..In addition to its acid-suppressing effect, the H2RA nizatidine also has a prokinetic action by suppressing acetylcholine esterase...
  3. Pae C, Kim J, Lee K, Lee C, Bahk W, Lee S, et al. Effect of nizatidine on olanzapine-associated weight gain in schizophrenic patients in Korea: a pilot study. Hum Psychopharmacol. 2003;18:453-6 pubmed
    A pilot study was conducted to evaluate the effect of nizatidine on olanzapine-associated weight gain (OAWG) in ten patients with schizophrenia and schizophreniform disorder in Korea...
  4. Furuta S, Kamada E, Suzuki T, Sugimoto T, Kawabata Y, Shinozaki Y, et al. Inhibition of drug metabolism in human liver microsomes by nizatidine, cimetidine and omeprazole. Xenobiotica. 2001;31:1-10 pubmed
    1. The inhibitory effects of cimetidine, nizatidine and omeprazole on the metabolic activity of CYP2C9, 2C19, 2D6 and 3A were investigated in human liver microsomes...
  5. Wu S, Ho Y, Wu H, Chen S, Ko H. Simultaneous determination of cimetidine, famotidine, nizatidine, and ranitidine in tablets by capillary zone electrophoresis. Electrophoresis. 2001;22:2758-62 pubmed
    ..CZE) method is described for the simultaneous determination of cimetidine (CIM), famotidine (FAM), nizatidine (NIZ), and ranitidine (RAN). The analysis of these drugs was performed in a 100 mM phosphate buffer, pH 3.5...
  6. Armstrong D, Pare P, Pericak D, Pyzyk M. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. Am J Gastroenterol. 2001;96:2849-57 pubmed
    ..The aim of this study was to compare pantoprazole 40 mg once daily versus nizatidine 150 mg b.i.d. in a mixed GERD patient population with ENRD or erosive esophagitis (Savary-Miller grades 1-3)...
  7. Memis D, Turan A, Karamanlioglu B, Guler T, Yurdakoc A, Pamukcu Z, et al. Effect of preoperative oral use of erythromycin and nizatidine on gastric pH and volume. Anaesth Intensive Care. 2002;30:428-32 pubmed
    This randomized controlled trial examined the effects of preoperative oral erythromycin or nizatidine on gastric pH and volume. Sixty patients, ASA 1 and 2 status scheduled for elective surgery were studied...
  8. Di Ciommo V, Ferrario F. [Nizatidine: a meta-analytical study]. Clin Ter. 1993;143:201-7 pubmed
    ..database was applied to search all randomized clinical trials published from 1986 to 1992 concerning the use of Nizatidine, a powerful H2-antagonist, versus other treatments, including placebo, in the treatment of duodenal ulcer ..
  9. Liu J, Sun D, He J, Yang C, Hu T, Zhang L, et al. Gastroprotective effects of several H2RAs on ibuprofen-induced gastric ulcer in rats. Life Sci. 2016;149:65-71 pubmed publisher
    ..screening of literature with the criteria of low toxicity led to four histamine-2 receptor antagonists (H2RAs): nizatidine, famotidine, lafutidine, and roxatidine acetate, which were selected for further investigation...
  10. Abdel Rahman S, Johnson F, Manowitz N, Holmes G, Kearns G. Single-dose pharmacokinetics of nizatidine (Axid) in children. J Clin Pharmacol. 2002;42:1089-96 pubmed
    The pharmacokinetics of nizatidine following a single 5.0 mg/kg oral dose given as an extemporaneous liquid formulation in apple juice was examined in 12 healthy children (8.0 +/- 2.4 years, 30.7 +/- 8.4 kg)...
  11. Blum R, Braverman A, Rice P, Johnson F. Pharmacokinetics and pharmacodynamics of a novel nizatidine controlled-release formulation in healthy subjects. J Clin Pharmacol. 2003;43:74-83 pubmed
    The pharmacokinetics and intragastric pH effects of a novel nizatidine controlled-release (CR) formulation were compared to a currently marketed immediate-release (IR) nizatidine formulation (Axid)...
  12. Dong H, Qiang Z, Lian J, Qu J. Degradation of nitro-based pharmaceuticals by UV photolysis: Kinetics and simultaneous reduction on halonitromethanes formation potential. Water Res. 2017;119:83-90 pubmed publisher
    ..e., ranitidine (RNTD) and nizatidine (NZTD)) during ultraviolet (UV) photolysis...
  13. Degim T, Zaimoglu V, Akay C, Degim Z. pH-Metric log K calculations of famotidine, naproxen, nizatidine, ranitidine and salicylic acid. Farmaco. 2001;56:659-63 pubmed
    ..The log K values of famotidine, naproxen, nizatidine, ranitidine and salicylic acid were determined using both shake flask method and potentiometric titrations...
  14. Al Ghannam S, Belal F. Spectrophotometric determination of three anti-ulcer drugs through charge-transfer complexation. J AOAC Int. 2002;85:1003-8 pubmed
    A simple charge-transfer complexation method is described for the spectrophotometric assay of nizatidine, ranitidine, and famotidine...
  15. Walash M, Belal F, Ibrahim F, Hefnawy M, Eid M. Kinetic spectrophotometric method for the determination of ranitidine and nizatidine in pharmaceuticals. J AOAC Int. 2002;85:1316-23 pubmed
    An accurate and simple kinetic method is described for the determination of ranitidine and nizatidine in pure form and in pharmaceuticals...
  16. Değim Z, Agabeyoglu I. Nonisothermal stability tests of famotidine and nizatidine. Farmaco. 2002;57:729-35 pubmed
    ..The stability and the degradation properties of famotidine and nizatidine were investigated using both isothermal and nonisothermal stability test techniques...
  17. Miyake K, Tsukui T, Shinji Y, Shinoki K, Hiratsuka T, Nishigaki H, et al. Teprenone, but not H2-receptor blocker or sucralfate, suppresses corpus Helicobacter pylori colonization and gastritis in humans: teprenone inhibition of H. pylori-induced interleukin-8 in MKN28 gastric epithelial cell lines. Helicobacter. 2004;9:130-7 pubmed
    ..divided into three groups, each group undergoing a 3-month treatment with either teprenone (150 mg/day), H2-RA (nizatidine, 300 mg/day), or sucralfate (3 g/day)...
  18. Wang X, Yang H, Zhou B, Wang X, Xie Y. Effect of oxidation on amine-based pharmaceutical degradation and N-Nitrosodimethylamine formation. Water Res. 2015;87:403-11 pubmed publisher
    Four pharmaceuticals (ranitidine, nizatidine, doxylamine, and carbinoxamine) were selected as model compounds to assess the efficiency of four oxidants (ozone (O3), chlorine (Cl2), chlorine dioxide (ClO2) and potassium permanganate (KMnO4)..
  19. Sailaja U, Shahin Thayyil M, Krishna Kumar N, Govindaraj G, Ngai K. Molecular mobility in the supercooled and glassy states of nizatidine and perphenazine. Eur J Pharm Sci. 2017;99:147-151 pubmed publisher
    The dielectric properties of two pharmaceuticals nizatidine and perphenazine were investigated in the supercooled liquid and glassy states by broadband dielectric spectroscopy...
  20. Lockyer M, Al Dgither S, Al Gaai E, Yousuf A, Hammami M. Bioequivalence of two oral formulations of nizatidine capsules in healthy male volunteers. Biopharm Drug Dispos. 2005;26:117-20 pubmed
    ..this randomized, crossover study was to compare the bioavailability of a generic and an innovator formulation of nizatidine 300 mg capsules under fasting conditions...
  21. Youssef R. Validated stability-indicating methods for the determination of nizatidine in the presence of its sulfoxide derivative. J AOAC Int. 2008;91:73-82 pubmed
    Four new selective, precise, and accurate methods are described for the determination of nizatidine (NIZ) in the presence of its sulfoxide derivative in both the raw material and pharmaceutical preparations...
  22. Wada Y, Ito M, Takata S, Kitamura S, Takamura A, Tatsugami M, et al. Little necessity of acid inhibition against proton pump inhibitor rebound effects and prior helicobacter pylori eradication therapy in gastric ulcer patients: a randomized prospective study. Hepatogastroenterology. 2009;56:624-8 pubmed
    ..After 8-week rabeprazole treatment for iatrogenic ulcer, they were randomly divided into two groups (who took nizatidine (group N) and sofalcone (group S)), and took each for 16 weeks, we compared RE/GERD symptoms with the baseline ..
  23. Morrissey K, Stocker S, Chen E, Castro R, Brett C, Giacomini K. The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Volunteers. Clin Pharmacokinet. 2016;55:495-506 pubmed publisher
    ..From this screen, nizatidine was identified and predicted to be a clinically potent and selective inhibitor of MATE2K-mediated transport...
  24. Iwakiri K, Kawami N, Sano H, Tanaka Y, Umezawa M, Futagami S, et al. The effects of nizatidine on transient lower esophageal sphincter relaxations (TLESRs) and acid reflux in healthy subjects. J Smooth Muscle Res. 2011;47:157-66 pubmed
    A study in Japan has found that nizatidine (NIZ) is more effective than other histamine H2 receptor agonists (H2RAs) in treating reflux esophagitis (RE), although the NIZ group included a greater number of patients with severe RE...
  25. Herszenyi L. [Treatment of gastroesophageal reflux disease]. Orv Hetil. 2003;144:2571-3 pubmed
  26. Nin T, Umemoto M, Negoro A, Miuchi S, Sakagami M. Nizatidine enhances salivary secretion in patients with dry mouth. Auris Nasus Larynx. 2008;35:224-9 pubmed
    It was reported that salivary secretion increased in 30 volunteers with administered nizatidine. The aim of the present study was to investigate whether or not nizatidine enhances salivary secretion and improves the function of salivary ..
  27. McCallum R, Zarling E, Goetsch A, Griffin C, Sarosiek I, Hejazi R, et al. Multicenter, double-blind, placebo-controlled crossover study to assess the acute prokinetic efficacy of nizatidine-controlled release (150 and 300 mg) in patients with gastroesophageal reflux disease. Am J Med Sci. 2010;340:259-63 pubmed publisher
    The aim of the study is to test whether nizatidine delivered via a unique bimodal pulsatile-controlled release system, nizatidine controlled release (CR), accelerates gastric emptying in patients with gastroesophageal reflux disease (GERD)..
  28. Sasaki M, Sudoh T, Fujimura A. Pharmacokinetics of ranitidine and nizatidine in very elderly patients. Am J Ther. 2005;12:223-5 pubmed
    This study was undertaken to examine whether the pharmacokinetic profiles of ranitidine and nizatidine, the H2 antagonists, differed with repeated doses in very elderly patients (>80 years old)...
  29. Hizawa K, Takeya T, Yao T, Yamamoto H, Aomi H, Nakahara T, et al. Gastric inflammatory polyposis after long-term intermittent use of nonsteroidal anti-inflammatory drugs and histamine2-receptor antagonists. Endoscopy. 2005;37:685 pubmed
  30. Reis de Sá A, Elkis H. Comments on "Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine". Rev Bras Psiquiatr. 2007;29:90; author reply 91 pubmed
  31. Darwish I, Hussein S, Mahmoud A, Hassan A. Spectrophotometric determination of H(2)-receptor antagonists via their oxidation with cerium(IV). Spectrochim Acta A Mol Biomol Spectrosc. 2008;69:33-40 pubmed
    ..method has been developed and validated for determination of H(2)-receptor antagonists: cimetidine, famotidine, nizatidine and ranitidine hydrochloride...
  32. Itokazu G, Fischer J, Manitpisitkul P, Hariharan R, Danziger L. Lack of effect of nizatidine-induced elevation of gastric pH on the oral bioavailability of dapsone in healthy volunteers. Pharmacotherapy. 2002;22:1420-5 pubmed
    ..Treatment B consisted of a single dose of dapsone 100 mg plus two doses of oral nizatidine 300 mg administered 3-4 hours apart to maintain gastric pH above 6.0...
  33. Abdel Rahman S, Johnson F, Connor J, Staiano A, Dupont C, Tolia V, et al. Developmental pharmacokinetics and pharmacodynamics of nizatidine. J Pediatr Gastroenterol Nutr. 2004;38:442-51 pubmed
    To characterize the impact of development on the pharmacokinetics and pharmacodynamics of nizatidine. Children (age range, 5 days-18 years) and adults (age range, 18-50 years) were enrolled in four open-label trials...
  34. Stauffer V, Lipkovich I, Hoffmann V, Heinloth A, McGregor H, Kinon B. Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis. BMC Psychiatry. 2009;9:12 pubmed publisher
    ..and a body mass index (BMI) > or = 25 kg/m2 who had received olanzapine treatment in combination with nizatidine (n = 68), sibutramine (n = 42), or amantadine (n = 48)...
  35. Futagami S, Yamawaki H, Izumi N, Shimpuku M, Kodaka Y, Wakabayashi T, et al. Impact of sleep disorders in Japanese patients with functional dyspepsia (FD): nizatidine improves clinical symptoms, gastric emptying and sleep disorders in FD patients. J Gastroenterol Hepatol. 2013;28:1314-20 pubmed publisher
    ..aim of this study is to evaluate the risk factors associated with sleep disorders and the clinical response to nizatidine therapy for sleep disorders in Rome III-based FD patients. We enrolled 94 FD patients and 52 healthy volunteers...
  36. Ashiru D, Patel R, Basit A. Simple and universal HPLC-UV method to determine cimetidine, ranitidine, famotidine and nizatidine in urine: application to the analysis of ranitidine and its metabolites in human volunteers. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;860:235-40 pubmed
    A validated, simple and universal HPLC-UV method for the determination of cimetidine, famotidine, nizatidine and ranitidine in human urine is presented...
  37. Kasama T, Shiozawa F, Isozaki T, Matsunawa M, Wakabayashi K, Odai T, et al. Effect of the H2 receptor antagonist nizatidine on xerostomia in patients with primary Sjögren's syndrome. Mod Rheumatol. 2008;18:455-9 pubmed publisher
    ..The aim of the present study was to assess the ability of nizatidine, an H2 receptor antagonist, to also relieve xerostomia in patients with primary SS...
  38. Hall J, Washabau R. Diagnosis and treatment of gastric motility disorders. Vet Clin North Am Small Anim Pract. 1999;29:377-95 pubmed
    ..Treatment consists of dietary management and gastric prokinetic agents. Cisapride is the drug of choice for treating delayed gastric emptying followed by erythromycin and ranitidine or nizatidine.
  39. Basit A, Newton J, Lacey L. Susceptibility of the H2-receptor antagonists cimetidine, famotidine and nizatidine, to metabolism by the gastrointestinal microflora. Int J Pharm. 2002;237:23-33 pubmed
    ..study was to assess the in vitro stability of the other H(2)-receptor antagonists, cimetidine, famotidine and nizatidine, to colonic bacteria...
  40. Tomokane Y, Nomura M, Kujime S, Noda Y, Kondo N, Nakaya Y, et al. Clinical study on the effects of nizatidine on gastric motility and cardiac autonomic function. Investigations using electrogastrography and spectral analysis of heart rate variability. Arzneimittelforschung. 2004;54:427-35 pubmed
    b>Nizatidine (CAS 76963-41-2, Acinon), an H2 receptor antagonist, not only inhibits acid secretion but also improves gastrointestinal motility...
  41. Teich J, Merchia P, Schmiz J, Kuperman G, Spurr C, Bates D. Effects of computerized physician order entry on prescribing practices. Arch Intern Med. 2000;160:2741-7 pubmed
    ..For medication selection, use of a computerized guideline resulted in a change in use of the recommended drug (nizatidine) from 15.6% of all histamine(2)-blocker orders to 81.3% (P<.001)...
  42. Hadden C. Adiabatic pulses in 1H-15N direct and long-range heteronuclear correlations. Magn Reson Chem. 2005;43:330-3 pubmed
    ..Additionally, the active pharmaceutical nizatidine was used as a model compound to demonstrate the improvements in the long-range correlation data.
  43. Esplugues J, Marti Cabrera M, Ponce J. [Safety of proton pump inhibitors]. Med Clin (Barc). 2006;127:790-5 pubmed
    ..After two decades of use, PPIs have proved to be very effective and safe drugs. ..
  44. He P, Davis S, Illum L. Sustained release chitosan microspheres prepared by novel spray drying methods. J Microencapsul. 1999;16:343-55 pubmed
    ..The addition of a wetting agent increased the release rate significantly. The coating of the microspheres with gelatin decreased the rate of release of drug in the presence of wetting agents. ..
  45. Paul K, Redman C, Chen M. Effectiveness and safety of nizatidine, 75 mg, for the relief of episodic heartburn. Aliment Pharmacol Ther. 2001;15:1571-7 pubmed
    The most frequent cause of episodic heartburn is food and beverage ingestion. Nizatidine, an H2-receptor antagonist, is currently approved for non-prescription use in the prevention and relief of heartburn at a dose of 75 mg up to twice a ..
  46. Devault K, Morgenstern D, Lynn R, Metz D. Effect of pantoprazole in older patients with erosive esophagitis. Dis Esophagus. 2007;20:411-5 pubmed
    ..Patients received pantoprazole 40 mg once daily, nizatidine 150 mg twice daily or placebo. Patients were evaluated for endoscopic healing at 4 and 8 weeks...
  47. Adachi K, Furuta K, Katsube T, Fujisawa T, Azumi T, Fujishiro H, et al. Nizatidine and cisapride increase salivary secretion in rats. Dig Dis Sci. 2004;49:399-403 pubmed
    ..Both nizatidine and cisapride are reported to increase acetylcholine concentrations in the postganglionic cholinergic synapses...
  48. Good C, Fultz S, Trilli L, Etchason J. Therapeutic substitution of cimetidine for nizatidine was not associated with an increase in healthcare utilization. Am J Manag Care. 2000;6:1141-6 pubmed
    To examine changes in healthcare utilization resulting from a formulary switch to cimetidine from nizatidine at the Veterans Affairs Pittsburgh Healthcare System...
  49. Klotz U, Gottlieb W, Keohane P, Dammann H. Nocturnal doses of ranitidine and nizatidine do not affect the disposition of diazepam. J Clin Pharmacol. 1987;27:210-2 pubmed
    ..crossover design): D + comedication of placebo and D + nocturnal dosing with 300 mg ranitidine or 300 mg nizatidine. Plasma concentrations of D and its major active metabolite, desmethyldiazepam (DD), were monitored by a gas-..
  50. Elshaboury S, Mohamed N, Ahmed S, Farrag S. An Efficient Ion-Pair Liquid Chromatographic Method for the Determination of Some H2 Receptor Antagonists. J Chromatogr Sci. 2016;54:419-28 pubmed publisher
    ..was developed and validated for the determination of some H2 receptor antagonists including ranitidine (RAN), nizatidine (NIZ) and famotidine (FAM)...
  51. Itoh H, Naito T, Takeyama M. Effects of histamine H(2)-receptor antagonists on human plasma levels of calcitonin gene-related peptide, substance P and vasoactive intestinal peptide. J Pharm Pharmacol. 2002;54:1559-63 pubmed
    The effects of the histamine H(2)-receptor antagonists (H(2)-antagonists), ranitidine, nizatidine, cimetidine and famotidine, on plasma levels of gastrointestinal peptides, calcitonin gene-related peptide (CGRP), substance P (SP), and ..
  52. Abdel Rahman S, Johnson F, Gauthier Dubois G, Weston I, Kearns G. The bioequivalence of nizatidine (Axid) in two extemporaneously and one commercially prepared oral liquid formulations compared with capsule. J Clin Pharmacol. 2003;43:148-53 pubmed
    b>Nizatidine (Axid) is an H2-receptor antagonist used for the treatment of acid-related gastrointestinal disorders...
  53. Apostu M, Dorneanu V. [Analytical application of phosphotungstic acid complexes. Fabrication and characterisation of membrane selective electrodes for some H2 antihistaminics]. Rev Med Chir Soc Med Nat Iasi. 2008;112:856-9 pubmed
    PVC matrix membrane selective electrodes for ranitidine, nizatidine and famotidine, based on sparingly soluble complexes, were prepared and characterized...
  54. Pare P, Meyer F, Armstrong D, Pyzyk M, Pericak D, Goeree R. Validation of the GSFQ, a self-administered symptom frequency questionnaire for patients with gastroesophageal reflux disease. Can J Gastroenterol. 2003;17:307-12 pubmed
    ..Patients with GERD participating in a randomized clinical trial comparing pantoprazole and nizatidine were asked to complete the GSFQ together with validated instruments for measurement of health-related quality of ..
  55. Wu S, Ho Y, Wu H, Chen S, Ko H. Head-column field-amplified sample stacking in capillary electrophoresis for the determination of cimetidine, famotidine, nizatidine, and ranitidine-HCl in plasma. Electrophoresis. 2001;22:2717-22 pubmed
    ..1-2.00 microg/mL cimetidine, 0.2-5.0 microg/mL ranitidine-HCl, 0.3-5.0 microg/mL nizatidine, and 0.1-3.0 microg/mL famotidine...
  56. Akimoto M, Hashimoto H, Shigemoto M, Maeda A, Yamashita K. Effects of antisecretory agents on angiogenesis during healing of gastric ulcers. J Gastroenterol. 2005;40:685-9 pubmed
    ..GH), and ulcer scars (GS) or a PPI group (P; given rabeprazole at 20 mg/day), or an H2-blocker group (H; given nizatidine at 800 mg/day)...
  57. Simpson P, Ooi C, Chong J, Smith A, Baldey A, Staples M, et al. Does the use of nizatidine, as a pro-kinetic agent, improve gastric emptying in patients post-oesophagectomy?. J Gastrointest Surg. 2009;13:432-7 pubmed publisher
    ..Animal models have shown that nizatidine, a histamine H2-receptor antagonist, has pro-kinetic properties and can accelerate gastric emptying...
  58. Nakano T, Kuroiwa T, Tsumita Y, Kaneko Y, Hiromura K, Ueki K, et al. Aplastic anemia associated with initiation of nizatidine therapy in a hemodialysis patient. Clin Exp Nephrol. 2004;8:160-2 pubmed
    We report on a hemodialysis (HD) patient in whom fatal aplastic anemia developed after the administration of nizatidine, a histamine 2 (H2)-receptor antagonist...
  59. Bhanji N, Margolese H. Extrapyramidal symptoms related to adjunctive nizatidine therapy in an adolescent receiving quetiapine and paroxetine. Pharmacotherapy. 2004;24:923-5 pubmed
    Weight gain is a serious problem with recently introduced atypical antipsychotic agents. Nizatidine, a histamine2 (H2)-receptor antagonist, may help reduce this weight gain...
  60. Apostu M, Dorneanu V, Bibire N. [Analytical application of phosphotungstic acid complexes. Synthesis and characterisation]. Rev Med Chir Soc Med Nat Iasi. 2007;111:530-4 pubmed
    ..Ranitidine, nizatidine and famotidine complexes with phosphotungstic acid were synthesized and subsequently characterized by their ..
  61. Haag S, Holtmann G. Onset of relief of symptoms of gastroesophageal reflux disease: post hoc analysis of two previously published studies comparing pantoprazole 20 mg once daily with nizatidine or ranitidine 150 mg twice daily. Clin Ther. 2010;32:678-90 pubmed publisher
    ..in patients with GERD or endoscopy-negative GERD (NERD) during the first 7 days of treatment with pantoprazole, nizatidine, or ranitidine...
  62. Koskenpato J, Punkkinen J, Kairemo K, Farkkila M. Nizatidine and gastric emptying in functional dyspepsia. Dig Dis Sci. 2008;53:352-7 pubmed
    In clinical practice, H2-receptor antagonists, including nizatidine, in addition to their use in the treatment of peptic ulcer and gastroesophageal reflux, are also useful in alleviating dyspeptic symptoms...
  63. Takahashi N, Miura M, Niioka T, Sawada K. Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients. Cancer Chemother Pharmacol. 2012;69:999-1004 pubmed publisher
    ..interaction between dasatinib and the gastric acid suppressants (H2-receptor antagonists (H2RA) famotidine and nizatidine and the proton pump inhibitor (PPI) lansoprazole in leukemia Japanese patients...
  64. Mimaki H, Kawauchi S, Kagawa S, Ueki S, Takeuchi K. Bicarbonate stimulatory action of nizatidine, a histamine H(2)-receptor antagonist, in rat duodenums. J Physiol Paris. 2001;95:165-71 pubmed
    b>Nizatidine, a histamine H(2)-antagonist, is known to inhibit acetylcholinesterase (AChE) activity and is used clinically as a gastroprokinetic agent as well as the anti-ulcer agent...
  65. Futagami S, Shimpuku M, Song J, Kodaka Y, Yamawaki H, Nagoya H, et al. Nizatidine improves clinical symptoms and gastric emptying in patients with functional dyspepsia accompanied by impaired gastric emptying. Digestion. 2012;86:114-21 pubmed publisher
    In this crossover study, we investigated whether nizatidine, a H(2)-receptor antagonist, can alleviate clinical symptoms and gastric emptying in patients with Rome III-based functional dyspepsia (FD) with or without impaired gastric ..
  66. Chen M, Jensen B, Zhai L, Colding H, Kharazmi A, Kristiansen J, et al. Nizatidine and omeprazole enhance the effect of metronidazole on Helicobacter pylori in vitro. Int J Antimicrob Agents. 2002;19:195-200 pubmed
    ..pylori to metronidazole. In this study, we have found that nizatidine, an H(2)-receptor antagonist, is also able to reduce the susceptibility of H...
  67. Orenstein S, Gremse D, Pantaleon C, Kling D, Rotenberg K. Nizatidine for the treatment of pediatric gastroesophageal reflux symptoms: an open-label, multiple-dose, randomized, multicenter clinical trial in 210 children. Clin Ther. 2005;27:472-83 pubmed
    ..in conjunction with the US Food and Drug Administration (FDA) to assess the tolerability and effectiveness of nizatidine, in different doses and formulations, including a newly formulated premade oral solution, for pediatric GERD...
  68. Weinberg D, Burnham D, Berlin J. Effect of histamine-2 receptor antagonists on blood alcohol levels: a meta-analysis. J Gen Intern Med. 1998;13:594-9 pubmed
    ..No such differences were noted for famotidine (0.28 mg/DL; 95% CI -1.24, 1.80) or nizatidine (2.33 mg/DL;, 95% CI -0.06, 4.72)...
  69. Itoh H, Nagano T, Takeyama M. Effect of nizatidine on paracetamol and its metabolites in human plasma. J Pharm Pharmacol. 2002;54:869-73 pubmed
    The effect of the histamine H2-receptor antagonist, nizatidine, on plasma concentrations of paracetamol has been investigated with respectto hepatic metabolism...
  70. Ueki S, Matsunaga Y, Yoneta T, Tamaki H, Itoh Z. Gastroprokinetic activity of nizatidine during the digestive state in the dog and rat. Arzneimittelforschung. 1999;49:618-25 pubmed
    The present study was undertaken to clarify a prokinetic activity of nizatidine (CAS 76963-41-2) during the digestive state as well as gastric emptying of a solid test meal in comparison with cimetidine (CAS 51481-61-9), famotidine (CAS ..
  71. Bochenek W, Mack M, Fraga P, Metz D. Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis. Aliment Pharmacol Ther. 2004;20:1105-14 pubmed
    ..To compare the safety and efficacy of pantoprazole, placebo and the H2 antagonist nizatidine in relieving symptoms in patients with erosive oesophagitis...